NASDAQ$AXGN
Axogen Inc. · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Axogen's third quarter performance demonstrated a return to growth, driven by improved commercial execution and the prioritization of nerve injury repair by surgeons and hospitals.
Axogen reported a 17% increase in net revenue to $33.4 million, with a gross margin of 83.0%. The company achieved adjusted net income of $1.5 million, or $0.04 per share, and an adjusted EBITDA of $2.3 million, marking a significant improvement compared to the previous year. The company ended the quarter with $106.7 million in cash, cash equivalents, and investments.
- Net revenue increased by 17% to $33.4 million compared to Q3 2019.
- Gross margin was 83.0%, a slight decrease from 84.2% in Q3 2019.
- Net loss improved to $1.5 million, or $0.04 per share, compared to a net loss of $5.6 million, or $0.14 per share, in Q3 2019.
- Adjusted net income was $1.5 million, or $0.04 per share, compared to an adjusted net loss of $2.6 million, or $0.07 per share, in Q3 2019.
Headline financials
Revenue & EPS history
Axogen · Revenue · Quarterly
$33.4M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+1.4%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+6.1%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+39.1%
Q2 2024
Best reaction
-27.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.6% | +9.9% | +2.6% | |
| Q4 2025 | -6.6% | -10.3% | -8.8% | |
| Q3 2025 | +22.8% | +28.6% | +58.5% | |
| Q1 2025 | -23.2% | -33.6% | -33.4% | |
| Q4 2024 | +11.7% | +11.1% | +5.4% | |
| Q3 2024 | -17.4% | -13.4% | -2.7% | |
| Q2 2024 | +39.1% | +42.2% | +64.4% | |
| Q1 2024 | -11.7% | -11.1% | +4.1% | |
| Q4 2023 | -14.4% | -17.4% | -26.7% | |
| Q3 2023 | +37.4% | +27.7% | +88.8% | |
| Q2 2023 | -20.8% | -27.9% | -27.0% | |
| Q1 2023 | -1.8% | -4.6% | -0.8% | |
| Q4 2022 | +11.6% | +9.2% | +37.8% | |
| Q3 2022 | +19.0% | +21.4% | +0.6% | |
| Q2 2022 | +2.1% | +1.2% | -10.7% | |
| Q1 2022 | +23.4% | +17.7% | +16.8% | |
| Q4 2021 | +8.0% | +27.1% | +6.2% | |
| Q3 2021 | -13.3% | -6.0% | -37.3% | |
| Q2 2021 | -2.5% | -9.5% | -12.5% | |
| Q1 2021 | +14.9% | +13.3% | -1.2% | |
| Q4 2020 | +3.6% | +7.0% | -7.7% | |
| Q3 2020 | +3.4% | +10.4% | +18.0% | |
| Q2 2020 | +0.3% | -2.3% | -1.7% | |
| Q1 2020 | -14.7% | -9.6% | +10.9% | |
| Q4 2019 | -17.6% | -15.8% | -36.3% | |
| Q3 2019 | +12.4% | +13.3% | +23.8% | |
| Q2 2019 | -27.3% | -21.8% | -5.5% | |
| Q1 2019 | -2.1% | -5.4% | -15.7% | |
| Q4 2018 | +1.6% | +6.7% | +13.4% | |
| Q3 2018 | +9.3% | +12.8% | -1.3% | |
| Q2 2018 | -12.6% | -13.1% | -2.4% | |
| Q1 2018 | -5.1% | +5.2% | +14.2% | |
| Q4 2017 | +8.8% | +4.5% | +17.0% | |
| Q3 2017 | +10.7% | +15.3% | +28.5% | |
| Q2 2017 | -4.8% | -6.4% | +14.7% | |
| Q1 2017 | +3.3% | +3.7% | +25.6% | |
| Q4 2016 | -0.5% | -0.5% | -5.2% | |
| Q3 2016 | -1.7% | -10.9% | -7.4% | |
| Q2 2016 | +25.1% | +26.2% | +32.9% | |
| Q1 2016 | -0.4% | — | — | |
| Q4 2015 | -4.7% | — | — | |
| Q3 2015 | +17.3% | — | — | |
| Q2 2015 | +5.4% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | +3.8% | — | — | |
| Q3 2014 | +5.5% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2014 | +1.6% | — | — | |
| Q4 2013 | -8.5% | — | — | |
| Q3 2013 | +1.8% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | -14.7% | — | — | |
| Q4 2012 | +4.5% | — | — | |
| Q3 2012 | -1.8% | — | — | |
| Q2 2012 | +18.2% | — | — | |
| Q1 2012 | +0.3% | — | — | |
| Q4 2011 | -4.5% | — | — | |
| Q3 2011 | -14.8% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | -6.8% | — | — | |
| Q3 2010 | +9.7% | — | — | |
| Q1 2010 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro